Published in Nature Genetics, the global study finds a strong link between FOXP4 expression and long COVID, offering new hope for diagnostic development.

A landmark global study has uncovered genetic variants linked to an increased risk of long COVID, marking an important step toward understanding the biology of the condition and creating early opportunities for targeted diagnostic innovation.

The research, “Genome-wide association study of long COVID” published in Nature Genetics, identified a significant genetic association between long COVID and variants in the FOXP4 gene, which influences lung function. Individuals with long COVID showed higher FOXP4 expression, with consistent risk patterns across diverse ancestry groups. These findings strengthen the hypothesis that lung-related immune pathways are central to long COVID, while recognising the syndrome’s broader manifestations, such as fatigue and cognitive impairment.

Implications for Future Diagnostics

For the clinical laboratory sector, these results provide a molecular starting point for the development of new diagnostic assays. While FOXP4 variants are not yet predictive at an individual level, they illuminate disease mechanisms that could inform future biomarker panels. In this context, Fast MDx’s open NGX 124 molecular diagnostics platform offers a flexible, high-throughput solution for research teams aiming to develop and validate FOXP4 variant assays. Its open architecture allows laboratories to design and deploy lab-developed tests (LDTs) quickly, enabling integration of genetic targets like FOXP4 into broader molecular screening strategies for post-viral syndromes.

As research advances, clinical laboratories will play a critical role in translating genetic discoveries into practical tools—validating biomarkers, embedding genetic and proteomic data into workflows, and supporting multi-disciplinary collaborations. Though clinically actionable tests may still be years away, the FOXP4 findings highlight how precision diagnostics, supported by open, adaptable platforms such as NGX 124, can accelerate the journey from genomic insight to patient benefit.

Global and Diverse Research Effort

The Long COVID Host Genetics Initiative analysed data from 33 independent studies in 19 countries, covering nearly 16,000 long COVID cases and 1.9 million controls. The inclusion of six genetic ancestry groups makes this one of the most comprehensive genome-wide association studies (GWAS) on the condition to date.

Previous reports from Today’s Clinical Lab in 2024 noted the rapid escalation of research interest—rising from just 105 published articles in 2020 to nearly 5,000 by 2023—as awareness of the scale and persistence of long COVID grew.

In addition to identifying genetic risk factors, the study confirmed a causal link between SARS-CoV-2 infection and long COVID, particularly after severe illness requiring hospitalisation. Overlaps were also found between long COVID-associated variants and those implicated in other diseases, underlining the interplay of genetic susceptibility and environmental factors.

Co-author Hanna Ollila, PhD, from the Institute for Molecular Medicine Finland and Massachusetts General Hospital, emphasised that while these variants are not as predictive as high-impact mutations like BRCA in breast cancer, they are crucial for mapping the biological systems involved—in this case, immune pathways affecting lung function. Larger sample sizes in future research will likely improve the resolution of genetic analysis, paving the way for specific, clinically useful biomarkers. However, Ollila cautioned that the development of routine diagnostic tools based on such findings may still be a decade or more away.